Contribution of liquid biopsy to diagnostics, genotyping and MRD monitoring in lymphoma

Diagnosis | Genotyping | MRD monitoring

UNMET NEEDS

PCNSL



MYD88



Spatial heterogeneity



50% interim PET/CT inconsistent with the final outcome in **DLDCL**

20-30% interim PET/CT results are inconsistent with the final outcome in **cHL**

SOLUTIONS

Liquid biopsy



CAPP-seq

Bioinformatic analyses

Progression



Rossi *et al.*, Haematologica, 2019